Search Results

The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that the first patient has been dosed in an investigator-initiated trial with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

Blue Earth Diagnostics today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18 F-rhPSMA-7.3 clinical data and images.

Immunome, Inc. today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer.

Laxxon Medical announced its participation in the 29th annual BIO-Europe Convention, taking place November 6-8, 2023 in Munich, Germany.

Obsidian Therapeutics, Inc. today announced the appointment of Dana Alexander as Chief Technical Officer.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.

Aktis Oncology today announced the promotion of Tyler Benedum, Ph.D., to Chief Technical Officer, effective immediately.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10th Gene Quantification Event held March 20-24 at the Technical University of Munich.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster announced the start of a Phase I clinical trial with ITM’s drug candidate ITM-31, a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.